• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • Instagram
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • What is ALS/MND
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights of People with ALS/MND and Caregivers
    • Research
      • Open Science
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven (Off-Label) Treatments
      • Open Label Extension
    • Advocacy
      • Advocacy Toolkit
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition and Swallowing
      • Occupational Therapy and Activities of Daily Living
      • Physiotherapy and Mobility
      • Respiratory Care
      • Speech Therapy and Communication
      • Support for Family & Caregivers
      • Technology
    • Drugs in Development
      • AB Science – Masitinib
      • Amylyx – AMX0035
      • Biogen – Tofersen
      • BrainStorm Cell Therapeutics – NurOwn
      • Clene Nanomedicine – CNM-Au8
      • Collaborative Medicinal Development – CuATSM
      • Cytokinetics – Reldesemtiv
      • Kadimastem – AstroRx
      • Mitsubishi Tanabe Pharma America – Oral Edaravone
      • Orphazyme – Arimoclomol
      • T Regulatory Cell Therapies
    • Approved Drugs
      • Radicava/Edaravone
      • Neudexta
      • Riluzole/Tiglutik
  • Support for Health Professionals
    • How to Break the News in ALS/MND
  • Events/Programs
    • Calendar of Events/Programs
    • Alliance Webinars
    • Alliance Meeting
    • Allied Professionals Forum
    • ALS/MND Connect
    • Global Day
    • March of Faces
    • International Symposium on ALS/MND
  • About
    • Who We Are
    • Board of Directors
    • Committees/Advisory Councils
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Innovation and Technology Council
      • Governance Committee
      • Budget and Finance Committee
    • Staff
    • History
    • Archives
      • Newsletters
      • Meetings
    • Awards
      • Student Award Nomination
      • Forbes Norris Award Nomination
      • Humanitarian Award Nomination
      • Allied Health Professional Award Nomination
  • Members
    • Member Registration
    • Forgot Password

Join the Alliance

The International Alliance of ALS/MND Associations encourages all organisations involved in support of people living with ALS/MND, and other organisations with an interest in ALS/MND, to apply for membership of the Alliance.

We have three levels of membership: Full, Affiliate, and Honorary. See below for criteria, application requirements, and fees for each membership level.

Membership Criteria, Application Requirements & Fees

Full Membership

The criteria for Full Membership in the Alliance will be Organisations which:

  • Serve people with ALS/MND or related disorders with a focus on patient advocacy;
  • Are chartered in own country as a non-profit national or independent organisation for at least 2 years;
  • Have a legal constitution or by-laws;
  • Are governed by a volunteer Board of Directors (however described), elected by and/or from the membership which includes people living with ALS/MND, carers, past carers, or people closely associated with the disease;
  • Prepare an annual financial statement; and,
  • Sign and fulfill the Alliance Code of Conduct

Prospective members must submit a cover letter stating their reasons for wanting to become a member of the International Alliance, which must be accompanied by the specified information below.

Applicants for Full Membership must submit the following documents in English:

  • Cover letter
  • Proof of non-profit status in their country
  • Copy of their constitution and/or by-laws
  • List of names of the Board of Directors (however described) and Officers
  • Mission or purpose statement (most likely in constitution)
  • Written financial statement of previous year’s income
  • Copies of brochures and other materials (if not in English, then with some English translation)

The fee for Full Membership is either an amount equal to 0.2% of total annual income of the applicant organisation or £UK100, which ever is greater. At the discretion of the Board of Directors, fees can be waived or reduced for members that demonstrate need and make a request in writing.

Affiliate Membership

The criteria for Affiliate Membership in the Alliance will be Organisations which:

  • Serve people with ALS/MND or related disorders with a focus on patient advocacy;
  • Are chartered in own country as a non-profit national or independent organisation (or status pending) by July 1st of the current membership year;
  • Have a legal constitution or by-laws;
  • Are governed by a volunteer Board of Directors (however described), elected by and/or from the membership which includes people living with ALS/MND, carers, past carers, or people closely associated with the disease;
  • Prepare an annual financial statement; and,
  • Sign and fulfill the Alliance Code of Conduct

Prospective members must submit a cover letter stating their reasons for wanting to become a member of the International Alliance, which must be accompanied by the specified information below.

Applicants for Affiliate Membership must submit the following documents in English:

  • Cover letter
  • Proof of non-profit status in their country
  • Copy of their constitution and/or by-laws
  • List of names of the Board of Directors (however described) and Officers
  • Mission or purpose statement (most likely in constitution)
  • Written financial statement of previous year’s income
  • Copies of brochures and other materials (if not in English, then with some English translation)

Subscriptions are £100 (pounds sterling).

Honorary Membership

Honourary membership may be conferred on key contributors to the Alliance at the discretion of the Board of Directors for service rendered in achieving the vison of the Alliance: A World Free of ALS/MND! These key contributors can be former Board Members, Patrons, Staff or Award winners.

 

For any questions or for further information, please contact the Executive Director at alliance@als-mnd.org.

The Board of Directors of the Alliance will review applications and supporting documentation received. Decisions are made at the Board of Directors Meetings, which are held quarterly. An email will be forwarded advising applicants of the Board’s decision.

Participation at the Alliance Meeting is encouraged for prospective new members. Observer status will be granted.

Primary Sidebar

  • David Bishop

    David Bishop

  • Monica Soriano, Diagnosed 2011 - Asociación ELA Argentina

    Monica Soriano, Diagnosed 2011 – Asociación ELA Argentina

  • Margreth Burger-Saile, Diagnosed 2011 - ALS Schweiz, Switzerland

    Margreth Burger-Saile, Diagnosed 2011 – ALS Schweiz, Switzerland

  • Chen Chun-Chin

    Chen Chun-Chin

  • Joyce Rusinak, Forbes Norris ALS Center, USA

    Joyce Rusinak, Forbes Norris ALS Center, USA

  • Fernando Ocampo Cardona, Colombia

    Fernando Ocampo Cardona, Colombia

  • Lachlan Terry, MND Australia, Diagnosed 2015, Australia

    Lachlan Terry, MND Australia, Diagnosed 2015, Australia

  • Karl Hughes, Diagnosed 2010 - IMNDA, Ireland

    Karl Hughes, Diagnosed 2010 – IMNDA, Ireland

  • Kirsten Harley, Diagnosed 2013 - Australia

    Kirsten Harley, Diagnosed 2013 – Australia

  • Eddy LeFrançois, Diagnosed 1992 - ALS Canada

    Eddy LeFrançois, Diagnosed 1992 – ALS Canada

  • Rolf Mauch, Association ALS Switzerland, Diagnosed 2015, Switzerland

    Rolf Mauch, Association ALS Switzerland, Diagnosed 2015, Switzerland

  • Ann Nicol

    Ann Nicol

  • Charlie “Hark” Dourney, Diagnosed 2007 - Hark ALS, USA

    Charlie “Hark” Dourney, Diagnosed 2007 – Hark ALS, USA

  • Brigitte Wernli, Association ALS Switzerland, Diagnosed 2014, Switzerland

    Brigitte Wernli, Association ALS Switzerland, Diagnosed 2014, Switzerland

  • Ian Roberts

    Ian Roberts

  • Jo Knowlton and her dog, Scotland

    Jo Knowlton and her dog, Scotland

  • Steven Gallagher, Canada

    Steven Gallagher, Canada

  • Elisabeth Zahnd, Switzerland

    Elisabeth Zahnd, Switzerland

  • Willi Klein

    Willi Klein

  • Nicholas (Nic) Bowman, MND Association of South Africa, Diagnosed 2016, Australia

    Nicholas (Nic) Bowman, MND Association of South Africa, Diagnosed 2016, Australia

  • Erwin Coppejans, Diagnosed 2007 - ALS Liga België, Belgium

    Erwin Coppejans, Diagnosed 2007 – ALS Liga België, Belgium

  • Soledad Rodriguez, FUNDELA, Diagnosed 2013, Spain

    Soledad Rodriguez, FUNDELA, Diagnosed 2013, Spain

  • Art Eggert, USA

    Art Eggert, USA

  • Sally Pauls, Diagnosed 2006 - Les Turner ALS Foundation

    Sally Pauls, Diagnosed 2006 – Les Turner ALS Foundation

  • Mary Thomas, Diagnosed 2013 - MND Australia

    Mary Thomas, Diagnosed 2013 – MND Australia

  • Mark Miller

    Mark Miller

  • Valdomiro Xavier Honório, Brazil

    Valdomiro Xavier Honório, Brazil

  • Shay Rishoni, Diagnosed 2011 - Prize4Life, Israel

    Shay Rishoni, Diagnosed 2011 – Prize4Life, Israel

  • Denis Blais, Diagnosed 2015 - ALS Canada

    Denis Blais, Diagnosed 2015 – ALS Canada

  • Norm MacIsaac, ALS Society of Canada, ALS Society of Quebec, Diagnosed 2014, Canada

    Norm MacIsaac, ALS Society of Canada, ALS Society of Quebec, Diagnosed 2014, Canada

  • Chris McCauley, Diagnosed 2015 - ALS Canada

    Chris McCauley, Diagnosed 2015 – ALS Canada

  • Zabun Nassar, MND Association, Diagnosed 2016, England

    Zabun Nassar, MND Association, Diagnosed 2016, England

  • Danny Reviers, Diagnosed 1979 - ALS Liga België, Belgium

    Danny Reviers, Diagnosed 1979 – ALS Liga België, Belgium

  • Joanne Pratt, Diagnosed 2011 - MND Australia

    Joanne Pratt, Diagnosed 2011 – MND Australia

  • Brian Lovell, Diagnosed 2011 - MND Australia

    Brian Lovell, Diagnosed 2011 – MND Australia

  • Guido De Mets, Belgium

    Guido De Mets, Belgium

  • Wilfried Leusing, Diagnosed 2010 - DGM, Germany

    Wilfried Leusing, Diagnosed 2010 – DGM, Germany

  • Steve Lufkin, USA

    Steve Lufkin, USA
    IMG_3993

  • Angie Bordaen, Diagnosed 2014 - ALS Liga België, Belgium

    Angie Bordaen, Diagnosed 2014 – ALS Liga België, Belgium

  • Jon Newsome, Les Turner ALS Foundation, USA

    Jon Newsome, Les Turner ALS Foundation, USA

  • Osiel Mendoza, Diagnosed 2016 - ALS Therapy Development Institute, USA

    Osiel Mendoza, Diagnosed 2016 – ALS Therapy Development Institute, USA

  • Marcel R. Wernard, Diagnosed 2016 - ALS Patients Connected, The Netherlands

    Marcel R. Wernard, Diagnosed 2016 – ALS Patients Connected, The Netherlands

  • Frank "Papa" Taylor

    Frank “Papa” Taylor

  • Phil Rossall, MND-Association, UK

    Phil Rossall, MND-Association, UK

  • Elkin Ramiro Gaviria Muñoz, Diagnosed  December 2018

    Elkin Ramiro Gaviria Muñoz, Diagnosed December 2018

  • Colm Francis Davis, Ireland

    Colm Francis Davis, Ireland

  • Cath Muir

    Cath Muir
    Cath

  • UK-Mahmood-Anwar

    UK-Mahmood-Anwar

  • Luis Antonio Pimenta Lima, Brazil

    Luis Antonio Pimenta Lima, Brazil

  • Juvenal Bayona Romero

    Juvenal Bayona Romero

Learn more about the March of Faces

Footer

Subscribe to our Bi-Monthly Newsletter

Sign up to receive updates and to hear what's going on in the International Alliance of ALS/MND Associations.

"*" indicates required fields

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • Instagram
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2023 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login